Stockscreener 앱 받기
434.30
1.01%
-4.41
시장 영업 전:
432.00
-2.30
-0.53%
Vertex Pharmaceuticals Inc 주식(VRTX)의 최신 뉴스
Halozyme announces global collaboration and license agreement with Vertex Pharmaceuticals for Hypercon(TM) technology - marketscreener.com
Halozyme Announces Global Collaboration And License Agreement With Vertex Pharmaceuticals For Hypercon™ Technology - TradingView
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology - PR Newswire
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vertex Pharmaceuticals Incorporated (VRTX) stock price, news, quote and history - Yahoo Finance UK
Vertex to Announce First Quarter 2026 Financial Results on May 4th - Business Wire
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Biotech layoff pick back up as 14 companies cut 745 jobs in Q1 - The Business Journals
Best Biotech Stocks To Follow NowApril 5th - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insider Sell: Joy Liu Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals EVP Sells $439,288 in Stock - National Today
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $439,288.26 in Stock - MarketBeat
Vertex (VRTX) legal chief sells 978 shares under 10b5-1 plan - Stock Titan
Vertex Pharmaceuticals Inc (VX1.MU) Stock Forum & Discussion - Yahoo! Finance Canada
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Growth and Technical Setup - ChartMill
Aberdeen Group Reduces Stake in Vertex Pharmaceuticals - National Today
Aberdeen Group plc Has $118.81 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
[ARS] VERTEX PHARMACEUTICALS INC / MA SEC Filing - stocktitan.net
Vertex (NASDAQ: VRTX) posts $12B 2025 revenue and sets 2026 proxy votes - Stock Titan
Vertex Pharmaceuticals: Label Expansions For ALYFTREK & TRIKAFTA Plus Strong Demand (VRTX) - Seeking Alpha
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday - AOL.com
The Opioid Crisis Was an Innovation Failure. Vertex Just Showed a Way to Fix It - inc.com
F&V Capital Management LLC Buys Shares of 3,645 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Allspring Global Investments Holdings LLC Cuts Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Banque Pictet & Cie SA - MarketBeat
Vertex Advances FDA Filing for IgA Nephropathy Therapy - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Submits Biologics Licensing Application for Accelerated FDA Approval - gurufocus.com
Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision - Yahoo Finance
Vertex Pharmaceuticals (NASDAQ: VRTX) reports 978-share Rule 144 resale and insider sales - Stock Titan
FDA Expands Vertex (VRTX) Drugs' Usage for Cystic Fibrosis - GuruFocus
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval of Expanded Use of ALYFTREK (Vanzacaftor/Tezacaftor/Ivacaftor) - marketscreener.com
Vertex Pharmaceuticals IncFDA expands indication for trikafta in cf patients ages 2 and older - marketscreener.com
Vertex wins FDA label expansion for cystic fibrosis drugs - Seeking Alpha
, Expanding Availability of These Medicines to ~95% of All People With CF in the United States - Business Wire
Vertex Pharmaceuticals (VRTX): Company Profile, Stock Price, News, Rankings - Fortune
Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Performance Indicators - Markets Mojo
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex (VRTX) CMO sells 2,329 shares in pre-set 10b5-1 trade - Stock Titan
Vertex Pharmaceuticals Incorporated Completes Submission of Biologics Licensing Application for Povetacicept to the U.S. Food and Drug Administration - marketscreener.com
[8-K] VERTEX PHARMACEUTICALS INC / MA Reports Material Event - Stock Titan
Promising Biotech Stocks To Watch NowMarch 31st - MarketBeat
Fierce Biotech Layoff Tracker 2026: Takeda plots 634 US job cuts - Fierce Biotech
Boston Common Asset Management LLC Sells 20,952 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness - simplywall.st
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vertex’s VX-407 Contraceptive Interaction Study Reaches Completion: What Investors Should Watch - TipRanks
BMO reiterates Vertex stock Outperform on cystic fibrosis strength By Investing.com - Investing.com UK
Best Biotech Stocks To Watch TodayMarch 29th - MarketBeat
Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta - TechStock²
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment - ChartMill
Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550 - Insider Monkey
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vanguard (VRTX) parent reports 0 shares; subsidiaries to report holdings separately - Stock Titan
Vertex Pharmaceuticals Tumbles Over 3.4% – What’s Behind the Sudden Drop? - Bitget
Vertex’s VX-407 Kidney Study Completion: What Phase 1 Progress Means For VRTX Investors - TipRanks
Carmen Bozic files Form 144; VRTX (NASDAQ: VRTX) insider sales listed - Stock Titan
0.16%
2.67%
자본화:
|
볼륨(24시간):